TAO Synergies Inc. (TAOX) shareholders
Close on Nov 17, 2026Market cap $13.99MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of TAOX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Vanguard Capital Management LLC | 118,471 | 1.58% | $441.90K | +39,102 | 0.00% |
| Citadel Advisors LLC | 83,172 | 1.11% | $310.23K | New | 0.00% |
| Geode Capital Management, LLC | 79,374 | 1.06% | $296.26K | −9,270 | 0.00% |
| Renaissance Technologies LLC | 78,817 | 1.05% | $293.99K | −22,983 | 0.00% |
| Summit Financial, LLC | 57,760 | 0.77% | $215.45K | +14,485 | 0.00% |
| Jane Street Group, LLC | 54,854 | 0.73% | $204.61K | New | 0.00% |
| BlackRock, Inc. | 45,898 | 0.61% | $171.20K | +26,145 | 0.00% |
| Hrt Financial LP | 40,072 | 0.54% | $149.00K | New | 0.00% |
| UBS Group AG | 32,779 | 0.44% | $122.27K | +22,029 | 0.00% |
| Vanguard Fiduciary Trust Co | 31,889 | 0.43% | $118.95K | −13,543 | 0.00% |
| State Street Corp | 25,200 | 0.34% | $94.00K | +5,900 | 0.00% |
| Morgan Stanley | 24,359 | 0.33% | $90.86K | – | 0.00% |
| Northern Trust Corp | 13,923 | 0.19% | $51.93K | +1,797 | 0.00% |
| Dimensional Fund Advisors LP | 12,619 | 0.17% | $47.07K | – | 0.00% |
| Ronald Blue Trust, Inc. | 2,832 | 0.04% | $10.56K | – | 0.00% |
| Steward Partners Investment Advisory, LLC | 2,800 | 0.04% | $10.44K | – | 0.00% |
| Massmutual Trust Co Fsb/Adv | 2,700 | 0.04% | $10.07K | – | 0.00% |
| Tower Research Capital LLC (TRC) | 2,413 | 0.03% | $9.00K | +2,337 | 0.00% |
| PNC Financial Services Group, Inc. | 750 | 0.01% | $2.80K | – | 0.00% |
| SBI Securities Co., Ltd. | 520 | 0.01% | $1.94K | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 29 | 1M | 9.5% | 6 / 9 | 5 / 2 | 0M | 0M |
| Q1 2026 | 25 | 0M | 6.3% | 8 / 5 | 4 / 8 | 0M | 0M |
| Q4 2025 | 26 | 1M | 7.9% | 11 / 6 | 4 / 8 | 0M | 0M |
| Q3 2025 | 23 | 0M | 4.7% | 14 / 5 | 1 / 3 | 0M | 0M |
| Q2 2025 | 12 | 0M | 0.8% | 5 / 2 | 1 / 4 | 0M | 0M |
| Q1 2025 | 11 | 0M | 0.7% | 3 / 4 | 1 / 0 | 0M | 0M |
| Q4 2024 | 8 | 0M | 0.3% | 1 / 2 | 1 / 1 | 0M | 0M |
| Q3 2024 | 8 | 0M | 0.0% | 3 / 1 | 2 / 2 | 0M | 0M |
| Q2 2024 | 8 | 0M | 0.1% | 8 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
12 funds held TAOX in Q2 2026, 65% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of TAOX | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 79,099 | 1.06% | $295.04K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 36,368 | 0.49% | $152.75K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 24,527 | 0.33% | $91.49K | 0.01% | Jun 30, 2026 |
| Fidelity Total Market Index Fund | 12,242 | 0.16% | $51.42K | 0.00% | May 31, 2026 |
| Dimensional U.S. Small Cap ETF | 11,119 | 0.15% | $36.58K | 0.00% | Jul 31, 2026 |
| Fidelity Series Total Market Index Fund | 9,860 | 0.13% | $41.41K | 0.00% | May 31, 2026 |
| Vanguard Total Stock Market Index Fund | 8,872 | 0.12% | $33.09K | 0.00% | Jun 30, 2026 |
| Fidelity Nasdaq Composite Index Fund | 7,014 | 0.09% | $29.46K | 0.00% | May 31, 2026 |
| 1290 VT Micro Cap Portfolio | 1,618 | 0.02% | $6.04K | 0.00% | Jun 30, 2026 |
| U.S. Micro Cap Portfolio | 800 | 0.01% | $2.63K | 0.00% | Jul 31, 2026 |
| State Street Balanced Index Fund | 398 | 0.01% | $1.48K | 0.00% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | -300 | -0.00% | -$1.12K | -0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Joshua Silverman | Executive Chairman, Director | 217,931 | 2.91% | Nov 17, 2026 |
| Alan J. Tuchman | Chief Medical Officer, Director | 3,909 | 0.05% | Feb 5, 2026 |
| Robert Weinstein | Chief Financial Officer | 16,574 | 0.22% | Nov 17, 2026 |
| Bruce Bernstein | Director | 80,897 | 1.08% | Nov 17, 2026 |
| William S. Singer | Director | 19,566 | 0.26% | Nov 17, 2026 |
| Robert Ephron | Director | 4,500 | 0.06% | Nov 17, 2026 |
| Jonathan Schechter | Director | 22,665 | 0.30% | Oct 17, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Joshua Silverman Executive Chairman, Director | Nov 13, 2026 | Award | +131,250 | – | – | 217,931 |
| Bruce Bernstein Director | Nov 13, 2026 | Award | +50,000 | – | – | 80,897 |
| Robert Weinstein Chief Financial Officer | Oct 17, 2025 | Tax withholding | −4,000 | $7.23 | $28.92K | 16,574 |
| Robert Weinstein Chief Financial Officer | Oct 17, 2025 | Award | +10,000 | – | – | 20,574 |
| Bruce Bernstein Director | Oct 17, 2025 | Award | +25,000 | – | – | 40,897 |
| Bruce Bernstein Director | Oct 17, 2025 | Tax withholding | −10,000 | $7.23 | $72.30K | 30,897 |
| Joshua Silverman Executive Chairman, Director | Oct 17, 2025 | Tax withholding | −40,000 | $7.23 | $289.20K | 86,681 |
| Joshua Silverman Executive Chairman, Director | Oct 17, 2025 | Award | +100,000 | – | – | 126,681 |
| William S. Singer Director | Oct 17, 2025 | Tax withholding | −6,000 | $7.23 | $43.38K | 19,566 |
| William S. Singer Director | Oct 17, 2025 | Award | +15,000 | – | – | 25,566 |
| Robert Ephron Director | Oct 17, 2025 | Tax withholding | −3,000 | $7.23 | $21.69K | 4,500 |
| Robert Ephron Director | Oct 17, 2025 | Award | +7,500 | – | – | 7,500 |
| Jonathan Schechter Director | Jun 30, 2025 | Award | +21,575 | – | – | 22,665 |
| Jonathan Schechter Director | Jun 30, 2025 | Tax withholding | −8,630 | $7.85 | $67.75K | 14,035 |
| William S. Singer Director | Jun 30, 2025 | Tax withholding | −6,164 | $7.85 | $48.39K | 10,566 |
| William S. Singer Director | Jun 30, 2025 | Award | +15,410 | – | – | 16,730 |
| Joshua Silverman Executive Chairman, Director | Jun 30, 2025 | Tax withholding | −16,768 | $7.85 | $131.63K | 26,681 |
| Joshua Silverman Executive Chairman, Director | Jun 30, 2025 | Award | +41,919 | – | – | 43,449 |
| Bruce Bernstein Director | Jun 30, 2025 | Award | +24,657 | – | – | 25,760 |
| Bruce Bernstein Director | Jun 30, 2025 | Tax withholding | −9,863 | $7.85 | $77.42K | 15,897 |
| Alan J. Tuchman Chief Medical Officer, Director | Jun 30, 2025 | Tax withholding | −1,726 | $7.85 | $13.55K | 3,909 |
| Alan J. Tuchman Chief Medical Officer, Director | Jun 30, 2025 | Award | +4,315 | – | – | 5,635 |
| Robert Weinstein Chief Financial Officer | Jun 30, 2025 | Award | +15,410 | – | – | 16,738 |
| Robert Weinstein Chief Financial Officer | Jun 30, 2025 | Tax withholding | −6,164 | $7.85 | $48.39K | 10,574 |
| Daniel L. Alkon President and CSO, Director | Dec 16, 2022 | Sale(10b5-1 plan) | −19,688 | $1.17 | $23.03K | 35,546 |
| William S. Singer Director | Dec 16, 2022 | Sale(10b5-1 plan) | −27,000 | $1.17 | $31.59K | 33,000 |
| Joshua Silverman Director | Dec 16, 2022 | Sale(10b5-1 plan) | −19,012 | $1.17 | $22.24K | 38,238 |
| Robert Weinstein Chief Financial Officer | Dec 16, 2022 | Sale(10b5-1 plan) | −27,000 | $1.17 | $31.59K | 33,198 |
| Bruce Bernstein Director | Dec 16, 2022 | Sale(10b5-1 plan) | −22,500 | $1.17 | $26.33K | 27,578 |
| Jonathan Schechter Director | Dec 16, 2022 | Sale(10b5-1 plan) | −20,250 | $1.17 | $23.69K | 28,500 |
| Alan J. Tuchman Chief Executive Officer, Director | Dec 16, 2022 | Sale(10b5-1 plan) | −27,000 | $1.17 | $31.59K | 33,000 |
| Daniel L. Alkon President and CSO, Director | Jul 13, 2021 | Award | +43,750 | – | – | 55,234 |
| Joshua Silverman Director | Jul 13, 2021 | Award | +42,250 | – | – | 57,250 |
| Alan J. Tuchman Chief Executive Officer, Director | Jul 13, 2021 | Award | +60,000 | – | – | 60,000 |
| William S. Singer Director | Jul 13, 2021 | Award | +60,000 | – | – | 60,000 |
| George Perry Director | Jul 13, 2021 | Award | +40,000 | – | – | 40,000 |
| Jonathan Schechter Director | Jul 13, 2021 | Award | +45,000 | – | – | 48,750 |
| Robert Weinstein Chief Financial Officer | Jul 13, 2021 | Award | +60,000 | – | – | 60,198 |
| Bruce Bernstein Director | Jul 13, 2021 | Award | +50,000 | – | – | 50,078 |
| Daniel L. Alkon See Remarks, Director | Jul 13, 2021 | Award | +80,000 | – | – | 91,484 |
| Joshua Silverman Director | Jul 13, 2021 | Award | +90,000 | – | – | 105,000 |
| Joshua Silverman Director | Jun 14, 2021 | Buy | +10,000 | $8.30 | $83.00K | 15,000 |
| Daniel L. Alkon Chief Scientific Officer, Director | Jun 14, 2021 | Buy | +10,000 | $8.26 | $82.60K | 11,484 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of TAO Synergies's stock actually held short. Settlement fails (shares not delivered on time) peaked at 43,936 shares on Sep 28, 2026 over the last 90 days.
See a number that looks wrong?